Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells

Oncology Reports

Volumn 34, Issue 1, 2015, Pages 518-524

  Deeb, Dorrah ^a   Gao, Xiaohua ^a   Liu, Yongbo ^a   Pindolia, Kirit ^a   Gautam, Subhash C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Apoptosis; hTERT; Pancreatic cancer; Pristimerin; Telomerase

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYC PROTEIN; PRISTIMERIN; PROTEIN KINASE B; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SP1; ANTINEOPLASTIC AGENT; TELOMERASE; TERT PROTEIN, HUMAN; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE SILENCING; MIAPACA CELL LINE; PANC 1 CELL LINE; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TERT GENE; TRANSCRIPTION REGULATION; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; DRUG EFFECTS; ENZYMOLOGY; GENE TARGETING; GENETICS; HUMAN; METABOLISM; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; GENE KNOCKDOWN TECHNIQUES; HUMANS; PANCREATIC NEOPLASMS; TELOMERASE; TRITERPENES;

EID: 84930023558     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3989     Document Type: Article

References (30)

1. Pancreatic Cancer-National Cancer Institute, U.S. National Institutes of Health: Cancer. Gov.http:www.cancer.gov/cancertopics/types/pancreatic. Retrieved 06-04-2010.
2. Maitra A and Hruban RH: Pancreatic cancer. Annu Rev Pathol 3: 157-188, 2008.
3. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
4. Mulcahy MF, Wahl AO and Small W Jr: The current status of combined radiotherapy and chemotherapy for locally advanced or resected pancreas cancer. J Natl Compr Canc Netw 3: 637-642, 2005.
5. Pino SM, Xiong HQ, McConkey D and Abbruzzese JL: Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep 6: 199-206, 2004.
6. Vaccaro V, Sperduti I and Milella M: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 365: 768-769, author reply 769, 2011.
7. Costa PM1, Ferreira PM, Bolzani Vda S, Furlan M, de Freitas Formenton Macedo Dos Santos VA, Corsino J, de Moraes MO, Costa-Lotufo LV, Montenegro RC and Pessoa C: Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro 22: 854-863, 2008.
8. Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP, Yuan X and Dou QP: Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem 103: 234-244, 2008.
9. Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG: The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction. Oncol Lett 5: 242-248, 2013.
10. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR and Wu YC: Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther 4: 1277-1285, 2005.
11. Wang Y, Zhou Y, Zhou H, Jia G, Liu J, Han B, Cheng Z, Jiang H, Pan S and Sun B: Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. PLoS One 7: e43826, 2012.
12. Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan J: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer 9: 112, 2010.
13. Deeb D, Gao X, Liu YB, Pindolia K and Gautam SC: Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2. Int J Oncol 44: 1707-1715, 2014.
14. Greider CW: Chromosome first aid. Cell 67: 645-647, 1991.
15. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991.
16. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR and Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6: 2011-2019, 1997.
17. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, et al: The RNA component of human telomerase. Science 269: 1236-1241, 1995.
18. Palm W and de Lange T: How shelterin protects mammalian telomeres. Annu Rev Genet 42: 301-334, 2008.
19. De Boeck G, Forsyth RG, Praet M and Hogendoorn PC: Telomere-associated proteins: Cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol 217: 327-344, 2009.
20. Blasco MA and Hahn WC: Evolving views of telomerase and cancer. Trends Cell Biol 13: 289-294, 2003.
21. Newbold RF: The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis 17: 539-550, 2002.
22. Janknecht R: On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett 564: 9-13, 2004.
23. Ohuchida K, Mizumoto K, Yamada D, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M and Tanaka M: Quantitative analysis of human telomerase reverse transcriptase in pancreatic cancer. Clin Cancer Res 12: 2066-2069, 2006.
24. Grochola LF, Greither T, Taubert HW, Möller P, Knippschild U, Udelnow A, Henne-Bruns D and Würl P: Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas. Neoplasia 10: 973-976, 2008.
25. Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Fukuda E, Sueda T and Hiyama E: Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery 143: 113-125, 2008.
26. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H and Inoue M: Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28: 669-677, 2000.
27. Konnikova L, Simeone MC, Kruger MM, Kotecki M and Cochran BH: Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 65: 6516-6520, 2005.
28. Kang SS, Kwon T, Kwon DY and Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274: 13085-13090, 1999.
29. Chung J, Khadka P and Chung IK: Nuclear import of hTERT requires a bipartite nuclear localization signal and Akt-mediated phosphorylation. J Cell Sci 125: 2684-2697, 2012.
30. Meeran SM, Ahmed A and Tollefsbol TO: Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 1: 101-116, 2010.